



Express Mail No. EL 989611990 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SINGH et al.	Docket No: 375462-012US
Serial No.: 10/631,029	Confirmation No.: 3056
Filed: July 29, 2003	Group Art Unit: 1614
For: METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS	Examiner: K. WEDDINGTON

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §§ 1.97 and 1.98, Applicant submits herewith patents, publications and/or other information (listed below and/or on the attached Substitute Form PTO 1449) that may be material to the examination of the captioned application, and in respect of which there may be a duty of disclosure as set forth in 37 CFR § 1.56, for consideration and to be made of record in the captioned application by the U.S. Patent and Trademark Office.

1. In accordance with 37 CFR 1.98, accompanying this Information Disclosure Statement are:
 - 1a. copies of: (i) each foreign patent listed on the attached Substitute Form PTO 1449; (ii) each publication listed on the attached Substitute Form PTO 1449, or that portion which caused it to be listed, *other than* U.S. patents and U.S. patent application publications; (iii) for each pending unpublished U.S. application, a copy of the application specification including the claims, and any drawing of the application, or that portion of the application which caused it to be listed including any

claims directed to that portion; and (iv) other information, or that portion which caused it to be listed herein or on the attached Substitute Form PTO-1449 (37 CFR § 1.98(a)(2)); and/or

- 1b. a concise explanation of relevancy, or an English language translation, of non-English language publications listed on the attached Substitute Form PTO-1449 (37 CFR § 1.98(a)(3)(i) & (ii)).
2. Copies of the documents listed on the attached Substitute Form PTO 1449 are not enclosed herewith, because the information was previously submitted to, or cited by, the U.S. Patent and Trademark Office in application Serial No. _____, of which the captioned application claims benefit under 35 U.S.C. § 120, and the Information Disclosure Statements submitted in that parent application complied with paragraphs (a) through (c) of 37 CFR § 1.98 (37 CFR § 1.98(d)).
3. This Information Disclosure Statement is filed under 37 CFR § 1.97(b):
 - 3a. within three months of the filing date of a national application other than a continued prosecution application under 37 CFR § 1.53(d);
 - 3b. within three months of the entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
 - 3c. before the mailing of a first Office Action on the merits; *or*
 - 3d. before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 CFR § 1.114. Accordingly, no certification or fee is required.
4. This Information Disclosure Statement is filed under CFR § 1.97(c) after the period specified by CFR § 1.97(b), but before the mailing date of any of a final Office Action under 37 CFR § 1.113, a notice of allowance under 37 CFR § 1.311, or an action that otherwise closes prosecution in the application, and is accompanied by one of:
 - 4a. the statement specified in 37 CFR § 1.97(e); *or*
 - 4b. the fee set forth in 37 CFR § 1.17(p).

5. This Information Disclosure Statement is filed under 37 CFR § 1.97(d) after the period specified by CFR § 1.97(c), but on or before payment of the issue fee, and is accompanied by:

5a. the statement specified in 37 CFR § 1.97(e); *and*

5b. the fee set forth in 37 CFR § 1.17(p).

6. Certification Statement (*applicable if Item 4a or 5a is checked*)

6a. In accordance with 37 CFR § 1.97(e)(1), the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; *or*

6b. In accordance with 37 CFR § 1.97(e)(2), the undersigned hereby states that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making a reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

7. Fee Statement and/or Authorization (*applicable if Item 4b or 5b is checked*)

7a. The fee set forth in 37 CFR § 1.17(p) is:

enclosed; *or*

to be charged to Dechert LLP Deposit Account No. 50-2778 (**Order No.: Docket No. 375462-012US (355218)**).

8. Additional materials (*if applicable*)

8a. a continuation application under 37 CFR § 1.53(b)(1) is filed concurrently herewith;

8b. a Request for Continued Examination under 37 CFR § 1.114 is filed concurrently herewith; *or*

8c. a Petition to Withdraw from issue under 37 CFR § 1.313(c)(2).

As specified in 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material information as defined in 37 CFR § 1.56(a) exists.

As specified in 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any information cited herein is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

Moreover, while the patents, publications and/or other information disclosed in this Information Disclosure Statement may be “material” pursuant to 37 CFR § 1.56, the Disclosure is not intended to constitute an admission that any patents, publications and/or other information included or referred to herein is “prior art” to the captioned application unless specifically designated as such.

Nothing herein shall constitute an admission concerning the contents of these references, nor shall the inclusion of these references be considered an admission that the references constitute prior art against the invention claimed in the above-identified application. Submission of the present documents shall not be construed as an admission that a search has been made or that better art does not exist.

While no fee beyond the \$180.00 fee set forth in 37 CFR § 1.17(p) is believed due in connection


with this paper, the Commissioner is authorized to charge any additional required fees, or credit any overpayment to DECHERT LLP Deposit Account No. 502778 (Order No. 375462-012US (355218)).

Please direct any calls in connection with this application to the undersigned at (650) 813-4800.


Date: February 22, 2006

DECHERT LLP
Customer No. 37509
Telephone: 650.813.4800
Facsimile: 650.813.4848

Respectfully submitted,


Ann M. Caviani Pease
Reg. No. 42,067

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/631029
				Filing Date	July 29, 2003
				First Named Inventor	Rajinder SINGH
				Art Unit	1614
				Examiner Name	K. WEDDINGTON
Sheet	1	of	1	Attorney Docket Number	
375462-012US (355218)					



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	10/355,543 (US 20040029902)	02-12-2004		
	A2	10/858,343 (US 20050038243)	02-17-2005		
	A3	11/299,207			
	A4	10/911,684 (US 20050209230)	09-22-2005		
	A5	11/148,746 (US 20060035916)	02-16-2006		
	A6	11/149,105 (US 20060025410)	02-06-2006		
	A7	11/149,418			
	A8	10/903,263 (US 20050234049)	10-20-2005		
	A9	10/903,870 (US 20050209224)	09-22-2005		
	A10	11/016,403 (US 20050192301)	09-01-2005		
	A11	10/913,270 (US 20050113398)	05-26-2005		
	A12	11/286,236			
	A13	11/133,419 (US 20060035891)	02-16-06		
	A14	11/216,532			
	A15	11/280,066			
	A16				
	A17				
	A18				

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1				

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	C1				
	C2				

Examiner Signature		Date Considered	12419946.1.BUSINESS
--------------------	--	-----------------	---------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2